Table 4.
Adverse events occurring in ≥2% of patients in either age group
| Adverse Event, n (%) |
Elderly |
Nonelderly |
||
|---|---|---|---|---|
|
1 mg |
2 mg |
2 mg |
3 mg |
|
| (n = 81) | (n = 83) | (n = 84) | (n = 77) | |
| Dysgeusia |
15 (18.5) |
23 (27.7) |
36 (42.9) |
44 (57.1) |
| Nasopharyngitis |
14 (17.3) |
18 (21.7) |
22 (26.2) |
14 (18.2) |
| Headache |
4 (4.9) |
5 (6.0) |
3 (3.6) |
1 (1.3) |
| Somnolence |
4 (4.9) |
2 (2.4) |
3 (3.6) |
6 (7.8) |
| Upper respiratory tract infection |
4 (4.9) |
3 (3.6) |
2 (2.4) |
4 (5.2) |
| Back pain |
4 (4.9) |
3 (3.6) |
2 (2.4) |
1 (1.3) |
| Blood creatine phosphokinase increased |
4 (4.9) |
1 (1.2) |
3 (3.6) |
2 (2.6) |
| Thirst |
3 (3.7) |
0 (0.0) |
2 (2.4) |
2 (2.6) |
| Glucose urine present |
3 (3.7) |
2 (2.4) |
1 (1.2) |
1 (1.3) |
| Dizziness |
1 (1.2) |
4 (4.8) |
0 (0.0) |
1 (1.3) |
| Pharyngitis | 1 (1.2) | 2 (2.4) | 3 (3.6) | 1 (1.3) |